RhumbLine Advisers
OCUL icon

RhumbLine Advisers’s Ocular Therapeutix OCUL Stock Holding History

RhumbLine Advisers’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.96M Sell
231,101
-10,220
-4% -$97.4K ﹤0.01% 1872
2025
Q4 		$2.93M Buy
241,321
+21,313
+10% +$259K ﹤0.01% 1671
2025
Q3 		$2.57M Sell
220,008
-5,540
-2% -$66.2K ﹤0.01% 1765
2025
Q2 		$2.09M Buy
225,548
+2,433
+1% +$19K ﹤0.01% 1860
2025
Q1 		$1.64M Buy
223,115
+9,514
+4% +$73.1K ﹤0.01% 1911
2024
Q4 		$1.82M Buy
213,601
+5,682
+3% +$55.4K ﹤0.01% 1933
2024
Q3 		$1.81M Sell
207,919
-3,382
-2% -$27.9K ﹤0.01% 1965
2024
Q2 		$1.45M Buy
211,301
+59,345
+39% +$366K ﹤0.01% 2053
2024
Q1 		$1.38M Buy
151,956
+37,991
+33% +$270K ﹤0.01% 2087
2023
Q4 		$508K Sell
113,965
-16,051
-12% -$47.5K ﹤0.01% 2648
2023
Q3 		$408K Buy
130,016
+7,793
+6% +$31.9K ﹤0.01% 2733
2023
Q2 		$631K Buy
122,223
+14,388
+13% +$85.6K ﹤0.01% 2542
2023
Q1 		$568K Buy
107,835
+6,492
+6% +$30.8K ﹤0.01% 2380
2022
Q4 		$285K Buy
101,343
+2,011
+2% +$6.66K ﹤0.01% 2693
2022
Q3 		$412K Buy
99,332
+8,837
+10% +$44.5K ﹤0.01% 2584
2022
Q2 		$364K Buy
90,495
+1,828
+2% +$6.91K ﹤0.01% 2654
2022
Q1 		$439K Buy
88,667
+1,549
+2% +$8.59K ﹤0.01% 2480
2021
Q4 		$607K Sell
87,118
-1,844
-2% -$14.3K ﹤0.01% 2428
2021
Q3 		$890K Buy
88,962
+3,845
+5% +$43.2K ﹤0.01% 2277
2021
Q2 		$1.21M Buy
85,117
+1,591
+2% +$24.2K ﹤0.01% 2156
2021
Q1 		$1.37M Sell
83,526
-2,189
-3% -$42.2K ﹤0.01% 2066
2020
Q4 		$1.77M Buy
85,715
+14,975
+21% +$222K ﹤0.01% 1909
2020
Q3 		$538K Sell
70,740
-5,655
-7% -$46.9K ﹤0.01% 2255
2020
Q2 		$636K Buy
76,395
+19,141
+33% +$127K ﹤0.01% 2236
2020
Q1 		$283K Buy
57,254
+1,544
+3% +$7.62K ﹤0.01% 2433
2019
Q4 		$220K Buy
55,710
+4,864
+10% +$16.9K ﹤0.01% 2718
2019
Q3 		$155K Buy
50,846
+605
+1% +$2.7K ﹤0.01% 2810
2019
Q2 		$221K Buy
50,241
+8,017
+19% +$29.7K ﹤0.01% 2754
2019
Q1 		$168K Sell
42,224
-1,241
-3% -$4.99K ﹤0.01% 2789
2018
Q4 		$173K Buy
43,465
+14,551
+50% +$80.2K ﹤0.01% 2776
2018
Q3 		$199K Sell
28,914
-1,288
-4% -$8.08K ﹤0.01% 2731
2018
Q2 		$204K Buy
30,202
+7,255
+32% +$49.8K ﹤0.01% 2730
2018
Q1 		$149K Buy
22,947
+1,625
+8% +$9.15K ﹤0.01% 2669
2017
Q4 		$95K Sell
21,322
-8,513
-29% -$43.5K ﹤0.01% 2779
2017
Q3 		$184K Buy
29,835
+2,449
+9% +$15.8K ﹤0.01% 2769
2017
Q2 		$254K Buy
27,386
+4,958
+22% +$48K ﹤0.01% 2639
2017
Q1 		$208K Buy
22,428
+3,493
+18% +$29.1K ﹤0.01% 2642
2016
Q4 		$158K Buy
18,935
+5,651
+43% +$43.8K ﹤0.01% 2727
2016
Q3 		$91K Buy
13,284
+230
+2% +$1.4K ﹤0.01% 2818
2016
Q2 		$65K Sell
13,054
-1,900
-13% -$18.8K ﹤0.01% 2954
2016
Q1 		$144K Hold
14,954
– – ﹤0.01% 2828
2015
Q4 		$140K Buy
14,954
+3,185
+27% +$34.4K ﹤0.01% 2894
2015
Q3 		$165K Buy
11,769
+1,444
+14% +$29K ﹤0.01% 2855
2015
Q2 		$217K Buy
+10,325
New +$256K ﹤0.01% 2848

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RhumbLine Advisers's OCUL Position: Q1 2026 in Review

RhumbLine Advisers reduced its Ocular Therapeutix (OCUL) stake by 4.2% in Q1 2026, selling an estimated $97.4K and leaving 231,101 shares worth $1.96M. The position accounts for ﹤0.01% of the portfolio, ranked #1872.

RhumbLine Advisers first reported a position in OCUL in Q2 2015 and has held it in 44 quarters since. The position peaked at $2.93M in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • RhumbLine Advisers held 231,101 shares of Ocular Therapeutix worth $1.96M as of Q1 2026.
  • RhumbLine Advisers sold 10,220 Ocular Therapeutix shares in Q1 2026, an estimated $97.4K.
  • Ocular Therapeutix made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #1872 holding.
  • RhumbLine Advisers first reported a position in Ocular Therapeutix in Q2 2015 and has held it in 44 quarters since.
  • RhumbLine Advisers's Ocular Therapeutix position peaked at $2.93M in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.